Creo Medical Group PLC Award of Shares under Share Incentive Plan (2438O)

TIDMCREO

RNS Number : 2438O

Creo Medical Group PLC

30 January 2023

Creo Medical Group plc

("Creo" or the "Company")

Award of Shares under Share Incentive Plan, Director Dealings, Issue of Equity and TVR

The Company implemented an HMRC approved Share Incentive Plan ("SIP") during 2020 which is available to all of the Company's UK based employees, including Directors.

Under the SIP, shares are acquired in four ways:

-- Partnership Shares where an employee can spend up to a GBP1,800 or 10% of their pre-tax income, whichever is the lower;

-- Matching Shares, where Creo can give up to two free Matching Shares for each Partnership Share bought. The plan requires employees to remain in employment for three years to benefit from the Matching Shares;

   --    Free Shares, where Creo can give up to GBP3,600 of free shares in any tax year; and 
   --    Dividend Shares where additional shares can be bought with any dividends paid. 

The Company has been notified that Fiduchi Trustees (UK) Limited, the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 408,923 ordinary shares in the Company ("Ordinary Shares"), at a price of GBP0.201 per Ordinary Share on 27(th) January 2023 to meet its obligations under the SIP. Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased, being 796,478 new Ordinary Shares (having taken into account 21,368 ordinary shares held by the Trust which were previously allocated to employees who ceased employment before the shares had vested). These new Ordinary Shares will be held by Fiduchi Trustees (UK) Limited as trustee of the SIP.

Craig Gulliford, Richard Rees and Christopher Hancock, executive directors of the Company (the "Participating Directors") have received Partnership Shares at a price of GBP0.201 per share and Matching Shares at a price of GBP0.001 per share in accordance with terms of the SIP (the "Transaction"). Following this the Participating Directors' shareholdings in the Company are as set out in the table below:

 
 Director                Total number of Ordinary       Total number of Ordinary 
                          Shares purchased or awarded    Shares held post Transaction 
                          under SIP 
 Craig Gulliford, 
  CEO                    13,434                         630,466 
                        -----------------------------  ------------------------------ 
 Richard Rees, CFO       13,434                         90,580 
                        -----------------------------  ------------------------------ 
 Christopher Hancock, 
  CTO                    13,440                         4,419,181 
                        -----------------------------  ------------------------------ 
 

Accordingly, the Company announces that it has made an application for 796,478 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 3 February 2023. Following the allotment and issue, the Company's issued share capital consists of 182,342,363 Ordinary Shares. The Company does not hold any shares in Treasury. As such the total number of shares in issue with voting rights is 182,342,363.

Total Voting Rights (TVR)

The above figure of 182,342,363 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.

Enquires:

 
 Creo Medical Group plc                                                  www.creomedical.com 
 Richard Rees (CFO)                                                      [phone] 
 
 Cenkos Securities plc                                                   [phone] 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Numis Securities Limited (Joint 
  Broker) 
  Freddie Barnfield / James Black 
  / Duncan Monteith                                                      [phone] 
 
 Walbrook PR Ltd                           Tel: + 44 ( 0)20 7933 8780 or [e-mail] 
 Paul McManus / Sam Allen /                           Mob: [phone] 
  Phillip Marriage                                             558 258 / [phone] 
 

About Creo Medical

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 
 1. Details of PDMR 
 a)   Name                       Craig Gulliford 
     -------------------------  ---------------------------------------- 
 b)   Position / status          CEO 
     -------------------------  ---------------------------------------- 
 c)   Initial notification       Initial notification 
       / amendment 
     -------------------------  ---------------------------------------- 
 2. Details of the transaction(s): section to be repeated for 
  (i) each type of instrument; (ii) each type of transaction; 
  (iii) each date; and (iv) each place where transactions have 
  been conducted 
 a)   Description of             Ordinary Shares 
       the financial 
       instrument 
     -------------------------  ---------------------------------------- 
 b)   Nature of the              Purchase of Ordinary Shares under Share 
       transaction                Incentive Plan 
     -------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)      Prices      Volume(s) 
                                   GBP0.201    4,478 
                                              ---------- 
     -------------------------  ---------------------------------------- 
 d)   Aggregated information     N/A - Single transaction 
 
       Aggregated volume 
       Price 
     -------------------------  ---------------------------------------- 
 e)   Date of the                2023-01-27 GMT 
       transaction 
     -------------------------  ---------------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
     -------------------------  ---------------------------------------- 
 
 
 1. Details of PDMR 
 a)   Name                       Craig Gulliford 
     -------------------------  ----------------------------------------------- 
 b)   Position / status          CEO 
     -------------------------  ----------------------------------------------- 
 c)   Initial notification       Initial notification 
       / amendment 
     -------------------------  ----------------------------------------------- 
 2. Details of the transaction(s): section to be repeated for 
  (i) each type of instrument; (ii) each type of transaction; 
  (iii) each date; and (iv) each place where transactions have 
  been conducted 
 a)   Description of             Ordinary Shares 
       the financial 
       instrument 
     -------------------------  ----------------------------------------------- 
 b)   Nature of the              Award of Ordinary Shares under Share Incentive 
       transaction                Plan 
     -------------------------  ----------------------------------------------- 
 c)   Price(s) and volume(s)      Prices      Volume(s) 
                                   GBP0.001    8,956 
                                              ---------- 
     -------------------------  ----------------------------------------------- 
 d)   Aggregated information     N/A - Single transaction 
 
       Aggregated volume 
       Price 
     -------------------------  ----------------------------------------------- 
 e)   Date of the                2023-01-27 GMT 
       transaction 
     -------------------------  ----------------------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
     -------------------------  ----------------------------------------------- 
 
 
 1. Details of PDMR 
 a)   Name                       Richard Rees 
     -------------------------  ---------------------------------------- 
 b)   Position / status          CFO 
     -------------------------  ---------------------------------------- 
 c)   Initial notification       Initial notification 
       / amendment 
     -------------------------  ---------------------------------------- 
 2. Details of the transaction(s): section to be repeated for 
  (i) each type of instrument; (ii) each type of transaction; 

  (iii) each date; and (iv) each place where transactions have 
  been conducted 
 a)   Description of             Ordinary Shares 
       the financial 
       instrument 
     -------------------------  ---------------------------------------- 
 b)   Nature of the              Purchase of Ordinary Shares under Share 
       transaction                Incentive Plan 
     -------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)      Prices      Volume(s) 
                                   GBP0.201    4,478 
                                              ---------- 
     -------------------------  ---------------------------------------- 
 d)   Aggregated information     N/A - Single transaction 
 
       Aggregated volume 
       Price 
     -------------------------  ---------------------------------------- 
 e)   Date of the                2023-01-27 GMT 
       transaction 
     -------------------------  ---------------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
     -------------------------  ---------------------------------------- 
 
 
 1. Details of PDMR 
 a)   Name                       Richard Rees 
     -------------------------  ----------------------------------------------- 
 b)   Position / status          CFO 
     -------------------------  ----------------------------------------------- 
 c)   Initial notification       Initial notification 
       / amendment 
     -------------------------  ----------------------------------------------- 
 2. Details of the transaction(s): section to be repeated for 
  (i) each type of instrument; (ii) each type of transaction; 
  (iii) each date; and (iv) each place where transactions have 
  been conducted 
 a)   Description of             Ordinary Shares 
       the financial 
       instrument 
     -------------------------  ----------------------------------------------- 
 b)   Nature of the              Award of Ordinary Shares under Share Incentive 
       transaction                Plan 
     -------------------------  ----------------------------------------------- 
 c)   Price(s) and volume(s)      Prices      Volume(s) 
                                   GBP0.001    8,956 
                                              ---------- 
     -------------------------  ----------------------------------------------- 
 d)   Aggregated information     N/A - Single transaction 
 
       Aggregated volume 
       Price 
     -------------------------  ----------------------------------------------- 
 e)   Date of the                2023-01-27 GMT 
       transaction 
     -------------------------  ----------------------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
     -------------------------  ----------------------------------------------- 
 
 
 1. Details of PDMR 
 a)   Name                       Christopher Hancock 
     -------------------------  ---------------------------------------- 
 b)   Position / status          CTO 
     -------------------------  ---------------------------------------- 
 c)   Initial notification       Initial notification 
       / amendment 
     -------------------------  ---------------------------------------- 
 2. Details of the transaction(s): section to be repeated for 
  (i) each type of instrument; (ii) each type of transaction; 
  (iii) each date; and (iv) each place where transactions have 
  been conducted 
 a)   Description of             Ordinary Shares 
       the financial 
       instrument 
     -------------------------  ---------------------------------------- 
 b)   Nature of the              Purchase of Ordinary Shares under Share 
       transaction                Incentive Plan 
     -------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)      Prices      Volume(s) 
                                   GBP0.201    4,480 
                                              ---------- 
     -------------------------  ---------------------------------------- 
 d)   Aggregated information     N/A - Single transaction 
 
       Aggregated volume 
       Price 
     -------------------------  ---------------------------------------- 
 e)   Date of the                2023-01-27 GMT 
       transaction 
     -------------------------  ---------------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
     -------------------------  ---------------------------------------- 
 
 
 1. Details of PDMR 
 a)   Name                       Christopher Hancock 
     -------------------------  ----------------------------------------------- 
 b)   Position / status          CTO 
     -------------------------  ----------------------------------------------- 
 c)   Initial notification       Initial notification 
       / amendment 
     -------------------------  ----------------------------------------------- 
 2. Details of the transaction(s): section to be repeated for 
  (i) each type of instrument; (ii) each type of transaction; 
  (iii) each date; and (iv) each place where transactions have 
  been conducted 
 a)   Description of             Ordinary Shares 
       the financial 
       instrument 
     -------------------------  ----------------------------------------------- 
 b)   Nature of the              Award of Ordinary Shares under Share Incentive 
       transaction                Plan 
     -------------------------  ----------------------------------------------- 
 c)   Price(s) and volume(s)      Prices      Volume(s) 
                                   GBP0.001    8,960 
                                              ---------- 
     -------------------------  ----------------------------------------------- 
 d)   Aggregated information     N/A - Single transaction 
 
       Aggregated volume 
       Price 
     -------------------------  ----------------------------------------------- 
 e)   Date of the                2023-01-27 GMT 
       transaction 
     -------------------------  ----------------------------------------------- 
 f)   Place of the transaction   London Stock Exchange 
     -------------------------  ----------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHURSWROKUAORR

(END) Dow Jones Newswires

January 30, 2023 03:51 ET (08:51 GMT)